Accelerating pooled licensing of medicines to enhance global production and equitable access.
作者信息
Shadlen Kenneth C
机构信息
Department of International Development, London School of Economics and Political Science, London, UK.
出版信息
Lancet. 2022 Aug 20;400(10352):632-634. doi: 10.1016/S0140-6736(22)01013-3. Epub 2022 Jul 8.
Abstract
摘要
相似文献
1
Accelerating pooled licensing of medicines to enhance global production and equitable access.
Lancet. 2022 Aug 20;400(10352):632-634. doi: 10.1016/S0140-6736(22)01013-3. Epub 2022 Jul 8.
2
Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines.
Glob Public Health. 2018 Oct;13(10):1430-1440. doi: 10.1080/17441692.2017.1407811. Epub 2017 Nov 28.
3
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.
4
Taking TRIPS to India--Novartis, patent law, and access to medicines.
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
5
6
The global health licensing program: a new model for humanitarian licensing at the university level.
Am J Law Med. 2009;35(2-3):281-309. doi: 10.1177/009885880903500203.
7
Learning from practice: compulsory licensing cases and access to medicines.
Pharm Pat Anal. 2012 Nov;1(5):555-75. doi: 10.4155/ppa.12.68.
8
Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region.
WHO South East Asia J Public Health. 2018 Sep;7(2):62-66. doi: 10.4103/2224-3151.239415.
9
TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
Chic J Int Law. 2002 Spring;3(1):27-46.
10
Commentary: Fulfilling the Promise of Global Access Licensing Principles to Enable Equitable Access.
Healthc Policy. 2022 May;17(4):37-44. doi: 10.12927/hcpol.2022.26828.
引用本文的文献
1
Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets.
JAMA Health Forum. 2025 Aug 1;6(8):e252043. doi: 10.1001/jamahealthforum.2025.2043.
2
Embedding a commitment to equitable global access into basic and early-phase translational research.
J Clin Transl Sci. 2025 Feb 25;9(1):e88. doi: 10.1017/cts.2024.691. eCollection 2025.
3
Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
Global Health. 2024 Jul 2;20(1):52. doi: 10.1186/s12992-024-01057-5.
4
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.
PLOS Glob Public Health. 2024 Jul 1;4(7):e0003418. doi: 10.1371/journal.pgph.0003418. eCollection 2024.
5
Life Science 2.0: reframing the life science sector for 'the benefit on mankind'.
Glob Health Action. 2024 Dec 31;17(1):2330758. doi: 10.1080/16549716.2024.2330758. Epub 2024 Apr 5.
6
Shaping the future of global access to safe, effective, appropriate and quality health products.
BMJ Glob Health. 2024 Jan 9;9(1):e014425. doi: 10.1136/bmjgh-2023-014425.
7
Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story.
BMJ Glob Health. 2023 Sep;8(9). doi: 10.1136/bmjgh-2023-012964.
8
Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!
Am J Respir Crit Care Med. 2023 Nov 1;208(9):915-916. doi: 10.1164/rccm.202307-1200VP.
9
Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!
Front Pharmacol. 2023 Mar 27;14:1163391. doi: 10.3389/fphar.2023.1163391. eCollection 2023.
本文引用的文献
1
Global drug diffusion and innovation with the medicines patent pool.
J Health Econ. 2022 Sep;85:102671. doi: 10.1016/j.jhealeco.2022.102671. Epub 2022 Aug 14.
2
It is not too late to achieve global covid-19 vaccine equity.
BMJ. 2022 Mar 24;376:e070650. doi: 10.1136/bmj-2022-070650.
3
How COVID-19 vaccine supply chains emerged in the midst of a pandemic.
World Econ. 2022 Feb;45(2):468-522. doi: 10.1111/twec.13183. Epub 2021 Oct 28.
4
Patent pooling to increase access to essential medicines.
Bull World Health Organ. 2019 Aug 1;97(8):575-577. doi: 10.2471/BLT.18.229179. Epub 2019 Jun 11.
5
Essential medicines for universal health coverage.
Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8.
6
Implementing socially responsible licensing for global health: beyond neglected diseases.
Sci Transl Med. 2014 Oct 29;6(260):260cm11. doi: 10.1126/scitranslmed.3009422.
7
The silent epidemic of exclusive university licensing policies on compounds for neglected diseases and beyond.
PLoS Negl Trop Dis. 2010 Mar 30;4(3):e570. doi: 10.1371/journal.pntd.0000570.
8
The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good.
Open AIDS J. 2010 Jan 19;4:37-40. doi: 10.2174/1874613601004020037.
9
Towards a Patent Pool for HIV Medicines: The Background.
Open AIDS J. 2010 Jan 19;4:33-6. doi: 10.2174/1874613601004020033.
Zotero 插件